Oncotelic's Recent Contributions to Cancer Research
Oncotelic Therapeutics, Inc. has recently made significant strides in the field of oncology by presenting its research efforts at a notable conference. Leading the charge is Dr. Cynthia Lee, who serves as the Vice President of Research and Development. Her commitment to advancing cancer treatments has made a profound impact, especially through the Sapu Bio pipeline of TGFB2 therapeutics.
The Presentations at SITC 2024
During the conference, Oncotelic showcased several vital research abstracts. Notably, Abstract Number 198 highlighted how TGFB2 mRNA levels interact with Interferon-alpha receptor activation of IRF9 and IFI27, which are important factors for tumor-associated macrophages that can influence overall survival rates in pancreatic ductal adenocarcinoma (PDAC). This research was co-authored by Sanjive Qazi, Cynthia Lee, and Vuong Trieu.
Transforming Growth Factor Beta 2
Abstract Number 218 delved into the potential prognostic impact of Transforming Growth Factor Beta 2 mRNA levels and their association with Interferon-gamma receptor activation. This analysis examined how these factors relate to the expression of CD276/B7-H3 in patients with low-grade gliomas, further establishing a scientific basis for targeted therapies. The authors involved in this presentation included Sanjive Qazi, Anthony Maida, and Vuong Trieu.
Meta-Analysis on Adverse Events in PDAC Treatments
Another significant presentation, Abstract Number 1444, focused on a meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival among PDAC patients who were treated with either mFOLFIRINOX or FOLFIRINOX despite having unresectable tumors. This abstract was crafted by an expert team including Vuong Trieu, Sanjive Qazi, Seymour Fein, Anthony Maida, and Tenshang Joh.
About Oncotelic Therapeutics
Oncotelic Therapeutics is at the cutting edge of treating rare diseases in the pediatric population, such as Diffuse Intrinsic Pontine Glioma (DIPG), through its collaboration with GMP Biotechnology Limited. Their innovative therapies extend into melanoma treatment using CA4P, and the company focuses keenly on Acute Myeloid Leukemia through another product, OXi 4503. In a bid to enhance its technological front, Oncotelic acquired PointR Data Inc. in late 2019, aiming to leverage artificial intelligence within biotechnology.
Future Developments
Oncotelic’s strategy includes the development of AL-101, a new treatment option delivered intranasally to address various disorders such as Parkinson's disease, erectile dysfunction, and hypoactive sexual desire disorder. Such conditions affect a large number of individuals, highlighting the urgent need for effective therapies.
Innovation in TGFB2 Therapeutics
The company is actively involved in pioneering first-in-class TGFB2 therapeutics specifically designed to treat pancreatic cancer and glioblastoma. Through its joint venture with Sapu Bio, Oncotelic is dedicated to driving this innovative work forward, laying the groundwork for clinical advancements that could transform treatment outcomes for patients.
Frequently Asked Questions
What was Oncotelic's focus at SITC 2024?
Oncotelic focused on presenting its advancements in TGFB2 therapeutics, highlighting their potential to impact cancer treatment.
Who presented Oncotelic’s research at the conference?
Dr. Cynthia Lee, the Vice President of Research and Development, led the presentations at SITC 2024.
What are some areas Oncotelic is targeting with its therapies?
Oncotelic is targeting treatments for diseases like pancreatic cancer, glioblastoma, Parkinson's disease, and various sexual dysfunction disorders.
How does Oncotelic utilize AI in its operations?
Oncotelic has integrated AI technologies through their acquisition of PointR Data Inc., aimed at enhancing their research and development capabilities.
What is the significance of TGFB2 in cancer research?
TGFB2 is being investigated for its role in tumor biology, potentially influencing therapeutic responses and patient survival.
